Compare ELUT & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELUT | BCTX |
|---|---|---|
| Founded | 2015 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.5M | 36.6M |
| IPO Year | 2020 | 2025 |
| Metric | ELUT | BCTX |
|---|---|---|
| Price | $0.84 | $3.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 100.2K | 84.8K |
| Earning Date | 11-05-2026 | 12-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.77 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,293,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.50 | $2.60 |
| 52 Week High | $1.39 | $13.90 |
| Indicator | ELUT | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 50.91 | 38.37 |
| Support Level | $0.74 | $3.35 |
| Resistance Level | $0.87 | $3.74 |
| Average True Range (ATR) | 0.06 | 0.21 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 65.53 | 9.08 |
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.